A patent judgment against Boston Scientific Corp. has jumped to $501 million after a Texas federal judge tacked on an additional $69 million in interest. U.S. District Judge John Ward ruled Thursday to expand the damages award -- decided by a federal jury in Marshall, Texas -- to cover interest on royalties dating back to the medical device maker's 2004 U.S. launch of drug-coated heart stents.
February 19, 2008 at 12:00 AM
1 minute read
The original version of this story was published on Law.com
A patent judgment against Boston Scientific Corp. has jumped to $501 million after a judge tacked on an additional $69 million in interest.
U.S. District Judge John Ward ruled Thursday to expand the damages award — decided by a federal jury in Marshall, Texas — to cover interest on royalties dating to the medical device maker’s 2004 U.S. launch of drug-coated heart stents.
Presented by BigVoodoo
Join the industry's top owners, investors, developers, brokers and financiers for the real estate healthcare event of the year!
This event shines a spotlight on how individuals and firms are changing the investment advisory industry where it matters most.
This conference aims to help insurers and litigators better manage complex claims and litigation.
We are seeking two attorneys with a minimum of two to three years of experience to join our prominent and thriving education law practice in...
Description: Fox Rothschild has an opening in the New York office for a Real Estate Litigation Associate with three to six years of commerci...
Downtown NY property and casualty defense law firm seeks a Litigation Associate with 3+ years' experience to become a part of our team! You ...
